Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

te blood cells. CLL is a B cell cancer that originates in the bone marrow. Approximately 16,000 patients in the US are diagnosed each year with CLL. The prevalence of CLL is approximately 113,000 in the US. The disease is a chronic disease of the elderly with an average survival of about 5 years. Patients commonly receive multiple lines of treatment over the course of their disease. CLL and Small lymphocytic lymphoma (SLL) are considered the same underlying disease. SLL is a disease that is limited to the lymph nodes.

About Ibrutinib

Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 26 trials are currently registered on www.clinicaltrials.gov.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that d
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
(Date:9/19/2014)... 19, 2014 According to ... (Benchtop, Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, ... & Rotary) & Geography - Global Trends & ... segments the lyophilization market on the basis of ... projections of the market size of each of ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Pressure ... today announced it has received and approved all ... HT48 instruments and has begun to manufacture the ... first instrument will be ready for shipment by ... built and released at a rate of about ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 The ... important partnership with the National Fire Protection Association ... The collaboration, formalized today in a Memorandum of ... Members, factories, workers and other stakeholders with information, ... help protect the health and safety of workers ...
(Date:9/19/2014)... to treat and cure disease is a hugely ... by the inability of doctors and scientists to effectively ... in patients without resorting to invasive procedures, like tissue ... the online journal Magnetic Resonance in Medicine , ... of Medicine, University of Pittsburgh and elsewhere describe the ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
(Date:9/19/2014)... Researchers at Jacksonville,s campus of Mayo Clinic have ... say contributes to both overproduction of toxic protein in ... well as loss of communication between neurons both ... study, in the online issue of Neuron ... defect with drugs "may rejuvenate or rescue this pathway," ...
Breaking Medicine News(10 mins):Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2
... Self-Funding,Healthcare Conference and Expo will provide employers and health ... both carriers and,brokers during a June 1-3, 2009 conference ... The conference is unique, as it is designed and ... Karrie Andes, Director of Human,Resources for Deffenbaugh Industries, ...
... (Nasdaq: DYNT ) today announced that a ... the SEC, gives the company until approximately June 28, ... bid rule."We are pleased that NASDAQ has further extended ... market environment," stated Kelvyn H. Cullimore Jr., chairman and ...
... tumors seen in mouse study , , MONDAY, Dec. 29 ... phosphates found in many natural and processed foods accelerated ... researchers report. , "Our study suggests that dietary regulation ... treatment as well as prevention," Myung-Haing Cho, lead author ...
... widespread media attention given to studies that have indicated ... new study shows just one-third of children who are ... pediatrician. The study, led by researchers at The ... Medicine in Cleveland, also stresses that this failure to ...
... Technology,Inc. ("Versus" or the "Company") announced revenues of ... compared to revenues of $5,566,000 for fiscal,year 2007. ... 31, 2008, were,$1,748,000 compared to revenues of $2,012,000 ... can vary significantly depending on the timing and,delivery ...
... MANHATTAN, KSThe Centers for Disease Control and Prevention and ... 30 minutes of moderate-intensity physical activity on most days ... optimal health. This recommendation is especially important for older ... requirement, yet are more at risk for chronic diseases ...
Cached Medicine News:Health News:Spending Too Much on Healthcare? This Employer-Designed Conference Will Inspire! 2Health News:NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance 2Health News:Food Phosphates Might Spur Lung Cancer 2Health News:Food Phosphates Might Spur Lung Cancer 3Health News:Can't chalk it up to 'baby fat' 2Health News:Versus Technology Announces Fiscal Year Results 2Health News:Versus Technology Announces Fiscal Year Results 3Health News:Versus Technology Announces Fiscal Year Results 4Health News:Versus Technology Announces Fiscal Year Results 5Health News:Versus Technology Announces Fiscal Year Results 6Health News:Versus Technology Announces Fiscal Year Results 7Health News:Another reason to get your hands dirty 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: